December 2nd 2011
£595 / $1040 / €745
Key facts, statistics and insights on 160 medium-sized generic manufacturers based in 35 countries!
Collaboration is the key to growth
In the current economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems.
At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of branded medicines have made moves to increase generic prescribing.
But pressure on health spending is seeing downward pressure on generic prices. With lower margins this is creating pain for generics companies.
SME Generic companies offer focused opportunities
With established markets compromised, where can the industry go? Expansion in the sector has been seen through more partnering, either through outright acquisition to increase market share or through product and marketing licensing. Being bigger and having improved market access is seen as a way of distributing cost and strengthening revenues. While major players such as Teva and Sandoz play an international role, there are a number of established and progressive generic manufacturers worthy of consideration.
Find and assess potential partners and acquisition targets with this report
This new report from Espicom is a key resource for the wide assessment of 160 medium-sized generic companies operating in 35 markets worldwide. The report provides an essential and comprehensive evaluation of each company:
About the Author: Generic Drugs: Global Collaboration Opportunities has been researched and written by Espicom editor Ian Platts. In addition to this report, Ian edits the leading newsletter World Generic Markets and has monitored the generics market for over 10 years. Other reports in the series;
Multi-therapy Drugs: Opportunities for Generics & Biosimilars
Highly-detailed analysis, outlook and forecasts of 24 leading drugs which are indicated for a range of critical conditions.
Hospital Injectable Drugs: Future Prospects for Generics & Biosimilars
The latest edition of Espicom’s best-selling injectables report focuses on hospital drugs in therapy areas such as cancer, thrombosis, rheumatoid arthritis and serious infection. The report examines the status, value and generic/biosimilar opportunity for over 30 high-growth injectable drugs.
World Generic Market Report 2011
Primary research with companies, statistics offices, health ministries and trade associations worldwide providing standard, comparative data and discussion on key issues.
Global Biosimilars: Identifying 2nd generation opportunities
A critical 206-page strategic management report which provides an analysis of the regulatory challenges and market opportunities for the biosimilar sector and assesses how it may practically develop.
Use this report to…
Delivering the key content you need...